Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: Recommendations on incorporating patient-reported outcomes in clinical trials in epithelial ovarian cancer.

[1]  A. Reuss,et al.  Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: recurrent disease , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  Young Tae Kim,et al.  Treatment preferences of advanced ovarian cancer patients for adding bevacizumab to first-line therapy. , 2016, Gynecologic oncology.

[3]  F. Fiteni,et al.  Statistical Challenges in the Analysis of Health-Related Quality of Life in Cancer Clinical Trials. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  M. Stockler,et al.  The patient-reported outcome content of international ovarian cancer randomised controlled trial protocols , 2016, Quality of Life Research.

[5]  Sarah T. Jewell,et al.  The association between clinician-based common terminology criteria for adverse events (CTCAE) and patient-reported outcomes (PRO): a systematic review , 2016, Supportive Care in Cancer.

[6]  M. King,et al.  Patient-reported outcomes (PRO) in ovarian cancer clinical trials-lost opportunities and lessons learned. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  M. Piccart,et al.  A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[8]  Adam P Dicker,et al.  American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  A. Gnanasakthy,et al.  Patient-Reported Outcomes in Cancer Drug Development and US Regulatory Review: Perspectives From Industry, the Food and Drug Administration, and the Patient. , 2015, JAMA oncology.

[10]  B. Monk,et al.  A cost-utility analysis of NRG Oncology/Gynecologic Oncology Group Protocol 218: incorporating prospectively collected quality-of-life scores in an economic model of treatment of ovarian cancer. , 2015, Gynecologic oncology.

[11]  A. Abernethy,et al.  Patient preferences in advanced or recurrent ovarian cancer , 2014, Cancer.

[12]  Henry C Kitchener,et al.  Ovarian cancer , 2014, The Lancet.

[13]  B. Monk,et al.  SGO guidance document for clinical trial designs in ovarian cancer: a changing paradigm. , 2014, Gynecologic oncology.

[14]  Amy P Abernethy,et al.  Development of the National Cancer Institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). , 2014, Journal of the National Cancer Institute.

[15]  P. Fayers,et al.  Patient-reported outcomes in randomised controlled trials of gynaecological cancers: investigating methodological quality and impact on clinical decision-making. , 2014, European journal of cancer.

[16]  D. Katsaros,et al.  Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial. , 2014, The Lancet. Oncology.

[17]  M. King,et al.  Patient-reported outcomes in ovarian cancer clinical trials. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[18]  D. Patrick.  Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension. , 2013, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[19]  T. Conroy,et al.  Impact of FOLFIRINOX compared with gemcitabine on quality of life in patients with metastatic pancreatic cancer: results from the PRODIGE 4/ACCORD 11 randomized trial. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  V. Gebski,et al.  Health-related quality of life in recurrent platinum-sensitive ovarian cancer--results from the CALYPSO trial. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[21]  P. Butow,et al.  Assessing Health-Related Quality of Life in Gynecologic Oncology: a Systematic Review of Questionnaires and Their Ability to Detect Clinically Important Differences and Change , 2009, International Journal of Gynecologic Cancer.

[22]  Y. Merrouche,et al.  From randomised clinical trials to clinical practice : a pragmatic cost-effectiveness analysis of Paclitaxel in first-line therapy for advanced ovarian cancer. , 2004, PharmacoEconomics.

[23]  潘凌亚,et al.  Ovarian Cancer , 2010, Cancer Treatment and Research.